anafranil
| Product dosage: 25mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 60 | $0.89 | $53.25 (0%) | 🛒 Add to cart |
| 90 | $0.80 | $79.87 $72.33 (9%) | 🛒 Add to cart |
| 120 | $0.76 | $106.49 $91.42 (14%) | 🛒 Add to cart |
| 180 | $0.72 | $159.74 $129.60 (19%) | 🛒 Add to cart |
| 270 | $0.69 | $239.61 $185.86 (22%) | 🛒 Add to cart |
| 360 | $0.68
Best per pill | $319.48 $243.12 (24%) | 🛒 Add to cart |
| Product dosage: 50mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $1.88 | $56.26 (0%) | 🛒 Add to cart |
| 60 | $1.47 | $112.52 $88.41 (21%) | 🛒 Add to cart |
| 90 | $1.35 | $168.78 $121.56 (28%) | 🛒 Add to cart |
| 120 | $1.28 | $225.04 $153.71 (32%) | 🛒 Add to cart |
| 180 | $1.22 | $337.56 $220.02 (35%) | 🛒 Add to cart |
| 270 | $1.17 | $506.34 $316.46 (37%) | 🛒 Add to cart |
| 360 | $1.15
Best per pill | $675.12 $414.92 (39%) | 🛒 Add to cart |
| Product dosage: 75mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.61 | $78.36 (0%) | 🛒 Add to cart |
| 60 | $2.09 | $156.73 $125.58 (20%) | 🛒 Add to cart |
| 90 | $1.92 | $235.09 $172.80 (26%) | 🛒 Add to cart |
| 120 | $1.84 | $313.45 $221.02 (29%) | 🛒 Add to cart |
| 180 | $1.76 | $470.18 $316.46 (33%) | 🛒 Add to cart |
| 270 | $1.70
Best per pill | $705.26 $459.12 (35%) | 🛒 Add to cart |
Synonyms | |||
Anafranil, known generically as clomipramine hydrochloride, is a tricyclic antidepressant (TCA) belonging to the dibenzazepine class. It’s primarily indicated for the treatment of obsessive-compulsive disorder (OCD), functioning as a potent serotonin reuptake inhibitor. Its significance in modern psychopharmacology stems from its robust efficacy in managing intrusive thoughts and compulsive behaviors, conditions notoriously resistant to many first-line interventions. While newer agents like SSRIs are often preferred initially due to tolerability, Anafranil remains a cornerstone for treatment-resistant cases, backed by decades of clinical evidence. Its role extends beyond OCD in some jurisdictions, including use for major depressive episodes and certain anxiety spectra, but its niche in OCD management is where it truly distinguishes itself.
Key Components and Bioavailability of Anafranil
The active pharmaceutical ingredient in Anafranil is clomipramine hydrochloride. It’s formulated for oral administration, available in immediate-release tablets (e.g., 10 mg, 25 mg, 50 mg) and, in some regions, as a solution for intravenous infusion in hospital settings for severe, acute cases. The hydrochloride salt enhances the compound’s stability and solubility, facilitating predictable gastrointestinal absorption.
Bioavailability is a critical consideration. After oral ingestion, clomipramine undergoes significant first-pass metabolism in the liver, primarily by cytochrome P450 enzymes, notably CYP2C19 and CYP2D6. This process converts it into its primary active metabolite, desmethylclomipramine. The parent drug is a more potent serotonin reuptake inhibitor, while the metabolite has greater affinity for norepinephrine reuptake inhibition. The ratio of clomipramine to desmethylclomipramine can vary significantly between individuals due to genetic polymorphisms in these enzymes, which directly influences both therapeutic effects and the side effect profile. This pharmacokinetic complexity is a key reason therapeutic drug monitoring (TDM) is often recommended, especially at higher doses or in cases of suboptimal response.
Mechanism of Action of Anafranil: Scientific Substantiation
The therapeutic action of Anafranil is predominantly attributed to its potent inhibition of the serotonin (5-HT) transporter. By blocking the reuptake of serotonin into the presynaptic neuron, it increases the concentration of this neurotransmitter in the synaptic cleft, thereby enhancing serotonergic neurotransmission. This mechanism is central to its anti-obsessional and anti-compulsive effects, as the serotonin system is heavily implicated in the pathophysiology of OCD.
However, its pharmacology isn’t selective. As a tricyclic compound, it also antagonizes several other receptors. It has high affinity for histamine H1 receptors (causing sedation), alpha-1 adrenergic receptors (contributing to orthostatic hypotension), and muscarinic cholinergic receptors (leading to anticholinergic side effects like dry mouth, constipation, and blurred vision). Its metabolite, desmethylclomipramine, contributes substantially to the norepinephrine reuptake inhibition, which can influence mood and energy but also adds to the side effect burden, such as tachycardia and tremors. Think of it as a powerful but somewhat “dirty” tool—highly effective for its primary target but with a broader pharmacological footprint than modern SSRIs. This is why we often see a trade-off: superior efficacy in some severe OCD cases but a less favorable tolerability profile.
Indications for Use: What is Anafranil Effective For?
Anafranil for Obsessive-Compulsive Disorder (OCD)
This is the primary and most well-substantiated indication. Numerous double-blind, placebo-controlled trials have consistently demonstrated its superiority over placebo and, in some head-to-head studies, over some SSRIs in reducing Yale-Brown Obsessive Compulsive Scale (Y-BOCS) scores. It’s often considered after failure of two or more adequate SSRI trials.
Anafranil for Major Depressive Disorder (MDD)
While not a first-line treatment for depression today due to its side effect profile, it is a potent antidepressant. It may be used for treatment-resistant depression or in cases where prominent anxiety or obsessive features accompany the depressive episode.
Anafranil for Panic Disorder and Other Anxiety Spectra
It has documented efficacy in reducing the frequency and severity of panic attacks. Its use in other anxiety conditions, like phobias or generalized anxiety disorder, is less common but supported by some older clinical literature.
Anafranil for Chronic Pain Syndromes
Off-label, its effect on central monoamine pathways can provide analgesic benefits in neuropathic pain conditions, similar to other tricyclics like amitriptyline.
Instructions for Use: Dosage and Course of Administration
Initiating Anafranil requires a low-and-slow approach to mitigate initial side effects. Treatment is typically long-term for chronic conditions like OCD.
| Indication | Initial Adult Dose | Titration & Target Dose | Administration Notes |
|---|---|---|---|
| OCD (Adults) | 25 mg daily | Increase by 25 mg every 3-4 days. Target: 100-250 mg/day in divided doses. Max: 250 mg/day. | Take with food to minimize GI upset. Higher doses often require divided dosing (BID/TID). |
| OCD (Children/Adolescents) | 25 mg daily | Very gradual titration. Target: 3 mg/kg/day or 100-200 mg/day, whichever is lower. | Close monitoring for behavioral activation or suicidal ideation is mandatory. |
| Depression (Adults) | 25 mg daily | Increase to 100-150 mg/day over 2 weeks. May go up to 250 mg/day if needed. | A single bedtime dose can help manage daytime sedation. |
Therapeutic effects for OCD may take 4 to 6 weeks or longer to become fully apparent. A minimum trial of 10-12 weeks at an adequate dose is recommended before deeming it ineffective. Abrupt discontinuation should be avoided; a gradual taper over weeks is necessary to prevent withdrawal symptoms (dizziness, nausea, headache).
Contraindications and Drug Interactions of Anafranil
Absolute contraindications include known hypersensitivity to clomipramine or other TCAs, concomitant use of monoamine oxidase inhibitors (MAOIs) due to risk of serotonin syndrome, and during the acute recovery phase after a myocardial infarction.
Significant drug interactions are a major clinical consideration:
- Serotonergic Agents: Combined use with other SRIs, tramadol, triptans, or St. John’s Wort increases serotonin syndrome risk.
- CYP2D6/CYP2C19 Inhibitors: Fluoxetine, paroxetine, cimetidine, and others can significantly increase clomipramine levels.
- QTc-Prolonging Agents: Concurrent use with other drugs that prolong the QT interval (e.g., certain antipsychotics, antiarrhythmics) increases the risk of Torsades de Pointes. Baseline and periodic ECG monitoring is advised.
- Anticholinergics: Additive anticholinergic effects with drugs like benztropine or diphenhydramine can lead to severe constipation, urinary retention, or confusion.
Use during pregnancy and lactation requires a careful risk-benefit analysis; it is generally avoided unless the benefits clearly outweigh potential risks to the fetus or neonate.
Clinical Studies and Evidence Base for Anafranil
The evidence for Anafranil in OCD is robust and foundational. The landmark 1989 multi-center, double-blind, crossover study by the Clomipramine Collaborative Study Group, published in Archives of General Psychiatry, was a game-changer. It conclusively demonstrated clomipramine’s superiority over placebo and the weakly active control clorgyline, solidifying the serotonergic hypothesis of OCD.
Subsequent meta-analyses, such as those reviewed by the Cochrane Collaboration, have consistently placed clomipramine at or near the top for efficacy compared to SSRIs, albeit with a higher dropout rate due to side effects. A 2019 network meta-analysis in JAMA Psychiatry reaffirmed its position as one of the most efficacious pharmacological treatments for OCD, though it ranked lower for acceptability.
Long-term studies have shown that a majority of responders can maintain benefits for over a year with continued treatment. The evidence for its use in depression, while older, is also strong, with its efficacy considered at least on par with later-generation antidepressants for severe, melancholic depression.
Comparing Anafranil with Similar Products and Choosing a Quality Product
When comparing Anafranil to SSRIs (e.g., fluoxetine, sertraline, fluvoxamine), the trade-off is clear: Anafranil often offers superior efficacy in refractory OCD but carries a heavier burden of anticholinergic, sedative, and cardiovascular side effects. SSRIs are better tolerated and safer in overdose, making them first-line. For a patient who has failed multiple SSRIs, however, Anafranil is a powerful next-step option.
Among TCAs, Anafranil is uniquely potent for serotonin reuptake inhibition. Compared to imipramine or amitriptyline, it is far more specific for OCD. Choosing a quality product is straightforward as Anafranil is a branded pharmaceutical, not a supplement. Prescribers should ensure they are sourcing from reputable, licensed pharmacies. Generic clomipramine is widely available and bioequivalent, offering a cost-effective alternative.
Frequently Asked Questions (FAQ) about Anafranil
What is the recommended course of Anafranil to achieve results for OCD?
A full therapeutic trial for OCD involves a gradual dose escalation over 2-4 weeks to a target dose of at least 100-150 mg/day, maintained for a minimum of 10-12 weeks. Significant improvement is often seen by week 4-6, but maximal benefit can take 3 months or more.
Can Anafranil be combined with SSRIs?
This combination is generally avoided due to the high risk of serotonin syndrome and potential for dangerous pharmacokinetic interactions (e.g., fluoxetine inhibiting clomipramine metabolism). Cross-tapering under close supervision is the safer approach.
What are the most common side effects of Anafranil?
The most frequent are anticholinergic (dry mouth ~85%, constipation ~50%, blurred vision), sedative (drowsiness ~50%), weight gain, sexual dysfunction, dizziness, and tremor. These often diminish over time but can be persistent.
Is weight gain inevitable with Anafranil?
Not inevitable, but very common. It’s attributed to antihistaminergic effects and possibly metabolic changes. Proactive lifestyle counseling regarding diet and exercise is crucial from the start of therapy.
Conclusion: Validity of Anafranil Use in Clinical Practice
In conclusion, Anafranil (clomipramine) remains a validated, high-efficacy agent in the psychiatric armamentarium, particularly for treatment-resistant obsessive-compulsive disorder. Its risk-benefit profile is characterized by potent therapeutic action counterbalanced by a significant side effect burden and safety considerations. For the appropriate patient—one who has not responded adequately to first-line SSRIs and is under careful medical supervision—Anafranil can be a transformative intervention. Its continued use is justified by a deep and enduring evidence base, securing its place as a powerful tool for managing severe, intrusive symptoms.
I remember when we first started using clomipramine in our clinic back in the late 90s. We were desperate for something that actually worked for the severe OCD cases. Sarah, a 28-year-old librarian, was washing her hands until they were raw, spending 6 hours a day on rituals. She’d failed fluoxetine and sertraline. We started her on Anafranil, and the first two weeks were rough—she was so sedated she could barely function, and the dry mouth was unbearable. The team was divided; my junior colleague wanted to pull the plug, arguing the side effects were unethical. I pushed to ride it out, based on some early data I’d seen from Europe. We split her dose, gave most of it at night, and by week 5, something shifted. She came in and said, for the first time in a decade, she’d read a book for pleasure without having to re-read paragraphs due to intrusive thoughts. It wasn’t a miracle—she still had symptoms—but it gave her a life back. We followed her for 5 years; she maintained on 150mg, got married, had a kid. She still sends a Christmas card every year. The funny thing is, we later discovered her CYP2D6 status was poor metabolizer, so her levels were sky-high. We got lucky. It taught me that with these old drugs, the therapeutic window is narrow, and you’re often flying a bit blind, but the payoff, when it works, is profound. You just have to manage the turbulence.